Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug
CA 2422759 A1 · Owner: Wust, Thomas · Inventors: Scheurich, Peter; Moosmayer, Dieter; Wust, Thomas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a polypeptide having preferably antitumoral and/or immunomodulating cytokine properties which can be activated by processing it in vivo. Said polypeptide comprises a central region that has a specific biological activity. At the C-terminus said region comprises a region with a processing unit and an inhibitor domain while at its N-terminus it comprises a region that selectively recognizes a macromolecule on a cell surface or a component of the extracellular matrix.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 17, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 17, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 17, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.